Resource

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Riddle, Matthew C; Rosenstock, Julio; Gerich, John
Diabetes care; 2003 Nov;26(11):3080-6. PMID: 14578243
Oregon Health and Science University, Portland, Oregon 97201, USA. riddlem@ohsu.edu
Category: 

Abstract

OBJECTIVE: To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c). RESEARCH DESIGN AND METHODS: In a randomized, open-label, parallel, 24-week multicenter trial, 756 overweight men and women with inadequate glycemic control (HbA(1c) >7.5%) on one or two oral agents continued prestudy oral agents and received bedtime glargine or NPH once daily, titrated using a simple algorithm seeking a target fasting plasma glucose (FPG)